Nationwide Fund Advisors’s Crescent Biopharma CBIO Stock Holding History

Nationwide Fund Advisors’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-149	Closed	-$208K	–	835
2017 Q3	$208K	Hold	149	–	–	﹤0.01%	2623
2017 Q2	$166K	Sell	149 -70	-32%	-$57.8K	﹤0.01%	2705
2017 Q1	$119K	Hold	219	–	–	﹤0.01%	2785
2016 Q4	$134K	Hold	219	–	–	﹤0.01%	2773
2016 Q3	$157K	Hold	219	–	–	﹤0.01%	2737
2016 Q2	$159K	Buy	219 +61	+39%	+$42K	﹤0.01%	2716
2016 Q1	$94K	Hold	158	–	–	﹤0.01%	2844
2015 Q4	$90K	Hold	158	–	–	﹤0.01%	2881
2015 Q3	$88K	Hold	158	–	–	﹤0.01%	2932
2015 Q2	$125K	Sell	158 -62	-28%	-$51.3K	﹤0.01%	2941
2015 Q1	$183K	Hold	220	–	–	﹤0.01%	2735
2014 Q4	$158K	Hold	220	–	–	﹤0.01%	2749
2014 Q3	$152K	Hold	220	–	–	﹤0.01%	2823
2014 Q2	$185K	Buy	220 +33	+18%	+$32.9K	﹤0.01%	2789
2014 Q1	$305K	Buy	+187	New	+$226K	﹤0.01%	2300

Other funds holding CBIO

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Nationwide Fund Advisors's CBIO Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Crescent Biopharma (CBIO) in Q4 2017, closing a stake of 149 shares — an estimated $208K sold.

Nationwide Fund Advisors first reported a position in CBIO in Q1 2014 and held it in 15 quarters. The position peaked at $305K in Q1 2014. 80 funds tracked by Wall St. Rank hold CBIO as of Q4 2017.

Nationwide Fund Advisors reported no remaining Crescent Biopharma position as of Q4 2017 after selling out during the quarter.
Nationwide Fund Advisors sold 149 Crescent Biopharma shares in Q4 2017, an estimated $208K.
Nationwide Fund Advisors first reported a position in Crescent Biopharma in Q1 2014 and held it in 15 quarters.
Nationwide Fund Advisors's Crescent Biopharma position peaked at $305K in Q1 2014.
80 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.